At the time of writing, Bicara Therapeutics Inc [BCAX] stock is trading at $13.26, up 4.74%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCAX shares have gain 1.22% over the last week, with a monthly amount drifted -3.00%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on February 06, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $31. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 06, 2024, and set its price target to $42. On November 05, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $48 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Stifel initiated its recommendation with a Buy and recommended $47 as its price target on October 08, 2024. Morgan Stanley started tracking with a Overweight rating for this stock on October 08, 2024, and assigned it a price target of $35. In a note dated October 08, 2024, Cantor Fitzgerald initiated an Overweight rating.
For the past year, the stock price of Bicara Therapeutics Inc fluctuated between $11.10 and $28.09. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $13.26 at the most recent close of the market. An investor can expect a potential return of 163.95% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.63 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.30 points at the first support level, and at 11.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.97, and for the 2nd resistance point, it is at 14.67.
Ratios To Look Out For
It is important to note that Bicara Therapeutics Inc [NASDAQ:BCAX] has a current ratio of 27.93. As well, the Quick Ratio is 27.93, while the Cash Ratio is 35.96.
Transactions by insiders
Recent insider trading involved Meisner Lara, Chief Legal Officer, that happened on Mar 14 ’25 when 79146.0 shares were sold. Officer, LARA S. MEISNER completed a deal on Mar 14 ’25 to buy 79146.0 shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 1.83 million shares on Sep 16 ’24.
